Conversely, the stimulatory effects of combined γ-tocotrienol and PPARγ agonist treatment in PPARγ negative or PPARγ silenced mammary tumor cells were associated with an increase in COX-2 and PGDS expression and corresponding increase in PGD2 synthesis. The gene discussed is PPARG; the disease is breast cancer.